Can aspirin resistance be clinically predicted in stroke patients?

Jung Im Seok, In Soo Joo, Jung Han Yoon, Yun Jung Choi, philhyu Lee, Kyoon Huh, Oh Young Bang

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objectives: Aspirin resistance is one of several possible explanations for limited efficacy or treatment failure of aspirin. However, the predictors of aspirin resistance are not well known. We therefore conducted a study of laboratory-defined aspirin resistance in Korean patients with ischemic stroke and considered a wide range of factors as possible predictors. Patients and methods: A total of 88 patients taking aspirin daily for the secondary prevention of stroke were included. Platelet function was assessed using the Rapid Platelet Function Assay-Aspirin (RPFA-ASA) system and the level of urinary thromboxane B2 (TX-B2). The result of the RPFA-ASA system was expressed as an aspirin reaction unit (ARU). We analyzed a wide range of factors including demographic data, stroke risk factors, and laboratory findings to identify the clinical predictors of aspirin resistance. Results: Eleven (12%) patients were identified as aspirin resistant by the ARU criteria. Univariate analysis showed that an older age, lower LDL cholesterol levels, and concurrent use of angiotensin converting enzyme inhibitors or receptor blockers were related to aspirin resistance by ARU criteria. Aspirin resistance by urinary TX-B2 criteria was observed in 18 (25%) patients and associated with an older age, metabolic syndrome, diabetes, cigarette smoking, and the use of angiotensin-converting enzyme inhibitors or receptor blockers. In multivariate analysis, this association lost significance by ARU criteria, and only lower fibrinogen levels were associated with increased risk by TX-B2 criteria. In addition, the stroke subtypes and the degree of atherosclerosis were not associated with aspirin resistance. The correlation between the two criteria was poor (r = -0.115, p = 0.34). Conclusion: Despite the comprehensive analysis of this study, we failed to identify independent predictors for laboratory-defined aspirin resistance. Additionally, little overlap was found between the two criteria with which to assess aspirin resistance.

Original languageEnglish
Pages (from-to)110-116
Number of pages7
JournalClinical Neurology and Neurosurgery
Volume110
Issue number2
DOIs
Publication statusPublished - 2008 Feb 1

Fingerprint

Aspirin
Stroke
Thromboxane B2
Angiotensin-Converting Enzyme Inhibitors
Blood Platelets
Secondary Prevention
Treatment Failure
LDL Cholesterol
Fibrinogen
Atherosclerosis
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Cite this

Seok, Jung Im ; Joo, In Soo ; Yoon, Jung Han ; Choi, Yun Jung ; Lee, philhyu ; Huh, Kyoon ; Bang, Oh Young. / Can aspirin resistance be clinically predicted in stroke patients?. In: Clinical Neurology and Neurosurgery. 2008 ; Vol. 110, No. 2. pp. 110-116.
@article{33491b807b244ec1a0efe6c0b3eeb153,
title = "Can aspirin resistance be clinically predicted in stroke patients?",
abstract = "Objectives: Aspirin resistance is one of several possible explanations for limited efficacy or treatment failure of aspirin. However, the predictors of aspirin resistance are not well known. We therefore conducted a study of laboratory-defined aspirin resistance in Korean patients with ischemic stroke and considered a wide range of factors as possible predictors. Patients and methods: A total of 88 patients taking aspirin daily for the secondary prevention of stroke were included. Platelet function was assessed using the Rapid Platelet Function Assay-Aspirin (RPFA-ASA) system and the level of urinary thromboxane B2 (TX-B2). The result of the RPFA-ASA system was expressed as an aspirin reaction unit (ARU). We analyzed a wide range of factors including demographic data, stroke risk factors, and laboratory findings to identify the clinical predictors of aspirin resistance. Results: Eleven (12{\%}) patients were identified as aspirin resistant by the ARU criteria. Univariate analysis showed that an older age, lower LDL cholesterol levels, and concurrent use of angiotensin converting enzyme inhibitors or receptor blockers were related to aspirin resistance by ARU criteria. Aspirin resistance by urinary TX-B2 criteria was observed in 18 (25{\%}) patients and associated with an older age, metabolic syndrome, diabetes, cigarette smoking, and the use of angiotensin-converting enzyme inhibitors or receptor blockers. In multivariate analysis, this association lost significance by ARU criteria, and only lower fibrinogen levels were associated with increased risk by TX-B2 criteria. In addition, the stroke subtypes and the degree of atherosclerosis were not associated with aspirin resistance. The correlation between the two criteria was poor (r = -0.115, p = 0.34). Conclusion: Despite the comprehensive analysis of this study, we failed to identify independent predictors for laboratory-defined aspirin resistance. Additionally, little overlap was found between the two criteria with which to assess aspirin resistance.",
author = "Seok, {Jung Im} and Joo, {In Soo} and Yoon, {Jung Han} and Choi, {Yun Jung} and philhyu Lee and Kyoon Huh and Bang, {Oh Young}",
year = "2008",
month = "2",
day = "1",
doi = "10.1016/j.clineuro.2007.09.005",
language = "English",
volume = "110",
pages = "110--116",
journal = "Clinical Neurology and Neurosurgery",
issn = "0303-8467",
publisher = "Elsevier",
number = "2",

}

Can aspirin resistance be clinically predicted in stroke patients? / Seok, Jung Im; Joo, In Soo; Yoon, Jung Han; Choi, Yun Jung; Lee, philhyu; Huh, Kyoon; Bang, Oh Young.

In: Clinical Neurology and Neurosurgery, Vol. 110, No. 2, 01.02.2008, p. 110-116.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Can aspirin resistance be clinically predicted in stroke patients?

AU - Seok, Jung Im

AU - Joo, In Soo

AU - Yoon, Jung Han

AU - Choi, Yun Jung

AU - Lee, philhyu

AU - Huh, Kyoon

AU - Bang, Oh Young

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Objectives: Aspirin resistance is one of several possible explanations for limited efficacy or treatment failure of aspirin. However, the predictors of aspirin resistance are not well known. We therefore conducted a study of laboratory-defined aspirin resistance in Korean patients with ischemic stroke and considered a wide range of factors as possible predictors. Patients and methods: A total of 88 patients taking aspirin daily for the secondary prevention of stroke were included. Platelet function was assessed using the Rapid Platelet Function Assay-Aspirin (RPFA-ASA) system and the level of urinary thromboxane B2 (TX-B2). The result of the RPFA-ASA system was expressed as an aspirin reaction unit (ARU). We analyzed a wide range of factors including demographic data, stroke risk factors, and laboratory findings to identify the clinical predictors of aspirin resistance. Results: Eleven (12%) patients were identified as aspirin resistant by the ARU criteria. Univariate analysis showed that an older age, lower LDL cholesterol levels, and concurrent use of angiotensin converting enzyme inhibitors or receptor blockers were related to aspirin resistance by ARU criteria. Aspirin resistance by urinary TX-B2 criteria was observed in 18 (25%) patients and associated with an older age, metabolic syndrome, diabetes, cigarette smoking, and the use of angiotensin-converting enzyme inhibitors or receptor blockers. In multivariate analysis, this association lost significance by ARU criteria, and only lower fibrinogen levels were associated with increased risk by TX-B2 criteria. In addition, the stroke subtypes and the degree of atherosclerosis were not associated with aspirin resistance. The correlation between the two criteria was poor (r = -0.115, p = 0.34). Conclusion: Despite the comprehensive analysis of this study, we failed to identify independent predictors for laboratory-defined aspirin resistance. Additionally, little overlap was found between the two criteria with which to assess aspirin resistance.

AB - Objectives: Aspirin resistance is one of several possible explanations for limited efficacy or treatment failure of aspirin. However, the predictors of aspirin resistance are not well known. We therefore conducted a study of laboratory-defined aspirin resistance in Korean patients with ischemic stroke and considered a wide range of factors as possible predictors. Patients and methods: A total of 88 patients taking aspirin daily for the secondary prevention of stroke were included. Platelet function was assessed using the Rapid Platelet Function Assay-Aspirin (RPFA-ASA) system and the level of urinary thromboxane B2 (TX-B2). The result of the RPFA-ASA system was expressed as an aspirin reaction unit (ARU). We analyzed a wide range of factors including demographic data, stroke risk factors, and laboratory findings to identify the clinical predictors of aspirin resistance. Results: Eleven (12%) patients were identified as aspirin resistant by the ARU criteria. Univariate analysis showed that an older age, lower LDL cholesterol levels, and concurrent use of angiotensin converting enzyme inhibitors or receptor blockers were related to aspirin resistance by ARU criteria. Aspirin resistance by urinary TX-B2 criteria was observed in 18 (25%) patients and associated with an older age, metabolic syndrome, diabetes, cigarette smoking, and the use of angiotensin-converting enzyme inhibitors or receptor blockers. In multivariate analysis, this association lost significance by ARU criteria, and only lower fibrinogen levels were associated with increased risk by TX-B2 criteria. In addition, the stroke subtypes and the degree of atherosclerosis were not associated with aspirin resistance. The correlation between the two criteria was poor (r = -0.115, p = 0.34). Conclusion: Despite the comprehensive analysis of this study, we failed to identify independent predictors for laboratory-defined aspirin resistance. Additionally, little overlap was found between the two criteria with which to assess aspirin resistance.

UR - http://www.scopus.com/inward/record.url?scp=38149124125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149124125&partnerID=8YFLogxK

U2 - 10.1016/j.clineuro.2007.09.005

DO - 10.1016/j.clineuro.2007.09.005

M3 - Article

VL - 110

SP - 110

EP - 116

JO - Clinical Neurology and Neurosurgery

JF - Clinical Neurology and Neurosurgery

SN - 0303-8467

IS - 2

ER -